PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32720318-0	2021	Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.	Anthracyclines	41-54	BRCA1 DNA repair associated	Homo sapiens	108-115	
32720318-2	2021	In this retrospective study, we aimed to explore the efficacy of anthracycline-taxane- or anthracycline-taxane/carboplatin-based neoadjuvant chemotherapy in BRCA1/2-mutated triple-negative breast cancer.	Anthracyclines	65-78	BRCA1 DNA repair associated	Homo sapiens	157-164	
32720318-2	2021	In this retrospective study, we aimed to explore the efficacy of anthracycline-taxane- or anthracycline-taxane/carboplatin-based neoadjuvant chemotherapy in BRCA1/2-mutated triple-negative breast cancer.	Anthracyclines	90-103	BRCA1 DNA repair associated	Homo sapiens	157-164	
32720318-10	2021	Our study suggested that BRCA1/2-mutated triple-negative breast cancer patients gain a survival benefit when carboplatin is added to standard anthracycline-taxane-based neoadjuvant chemotherapy.	Anthracyclines	142-155	BRCA1 DNA repair associated	Homo sapiens	25-32